| A microRNA DNA methylation signature for human cancer metastasis A Lujambio, GA Calin, A Villanueva, S Ropero, M Sánchez-Céspedes, ... Proceedings of the National Academy of Sciences 105 (36), 13556-13561, 2008 | 1366 | 2008 |
| The microcosmos of cancer A Lujambio, SW Lowe Nature 482 (7385), 347-355, 2012 | 1357 | 2012 |
| Genetic unmasking of an epigenetically silenced microRNA in human cancer cells A Lujambio, S Ropero, E Ballestar, MF Fraga, C Cerrato, F Setién, ... Cancer research 67 (4), 1424-1429, 2007 | 1171 | 2007 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 975 | 2021 |
| Non-cell-autonomous tumor suppression by p53 A Lujambio, L Akkari, J Simon, D Grace, DF Tschaharganeh, JE Bolden, ... Cell 153 (2), 449-460, 2013 | 817 | 2013 |
| β-catenin activation promotes immune escape and resistance to anti–PD-1 therapy in hepatocellular carcinoma M Ruiz de Galarreta, E Bresnahan, P Molina-Sánchez, KE Lindblad, ... Cancer discovery 9 (8), 1124-1141, 2019 | 713 | 2019 |
| A combinatorial strategy for treating KRAS-mutant lung cancer E Manchado, S Weissmueller, JP Morris, CC Chen, R Wullenkord, ... Nature 534 (7609), 647-651, 2016 | 439 | 2016 |
| Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu, H Koeppen, W Zhang, ... Nature medicine 28 (8), 1599-1611, 2022 | 350 | 2022 |
| The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer AF Fernandez, C Rosales, P Lopez-Nieva, O Graña, E Ballestar, ... Genome research 19 (3), 438-451, 2009 | 314 | 2009 |
| CpG island hypermethylation of tumor suppressor microRNAs in human cancer A Lujambio Cell cycle 6 (12), 1454-1458, 2007 | 314 | 2007 |
| The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma R Donne, A Lujambio Hepatology 77 (5), 1773-1796, 2023 | 303 | 2023 |
| Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma J Bollard, V Miguela, MR De Galarreta, A Venkatesh, CB Bian, ... Gut 66 (7), 1286-1296, 2017 | 279 | 2017 |
| CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer A Lujambio, A Portela, J Liz, SA Melo, S Rossi, R Spizzo, CM Croce, ... Oncogene 29 (48), 6390-6401, 2010 | 227 | 2010 |
| CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma CH Huang, A Lujambio, J Zuber, DF Tschaharganeh, MG Doran, ... Genes & development 28 (16), 1800-1814, 2014 | 215 | 2014 |
| How epigenetics can explain human metastasis: a new role for microRNAs A Lujambio, M Esteller Cell cycle 8 (3), 377-382, 2009 | 194 | 2009 |
| An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling Z Karoulia, Y Wu, TA Ahmed, Q Xin, J Bollard, C Krepler, X Wu, C Zhang, ... Cancer cell 30 (3), 485-498, 2016 | 193 | 2016 |
| Integrin beta 3 regulates cellular senescence by activating the TGF-β pathway V Rapisarda, M Borghesan, V Miguela, V Encheva, AP Snijders, ... Cell reports 18 (10), 2480-2493, 2017 | 182 | 2017 |
| A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer SJ Vidal, V Rodriguez-Bravo, SA Quinn, R Rodriguez-Barrueco, ... Cancer cell 27 (2), 223-239, 2015 | 154 | 2015 |
| To clear, or not to clear (senescent cells)? That is the question A Lujambio Bioessays 38, S56-S64, 2016 | 143 | 2016 |
| Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16, activation of the DNA damage response pathway D Blanco, S Vicent, MF Fraga, I Fernandez-Garcia, J Freire, A Lujambio, ... Neoplasia 9 (10), 840-IN12, 2007 | 142 | 2007 |
